Bayer (FRA:BAYN) has been assigned a €70.00 ($81.40) price objective by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Wednesday. The firm presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 15.09% from the stock’s current price.
Several other research firms also recently commented on BAYN. Societe Generale set a €72.00 ($83.72) price objective on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, December 6th. UBS Group reaffirmed a “buy” rating and issued a price objective on shares of Bayer in a report on Wednesday, January 2nd. Goldman Sachs Group set a €78.00 ($90.70) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Wednesday. Warburg Research set a €88.50 ($102.91) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Friday, November 30th. Finally, Barclays set a €85.00 ($98.84) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Monday, March 4th. Eight equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of €88.67 ($103.11).
BAYN opened at €60.82 ($70.72) on Wednesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.